452972-07-5

Basic information

• Product Name: 3-BROMO-5-(4-METHOXYPHENYL)PYRIDINE
• Synonyms: 3-BROMO-5-(4-METHOXYPHENYL)PYRIDINE;Pyridine, 3-broMo-5-(4-Methoxyphenyl)-
• CAS NO: 452972-07-5
• Molecular Formula: C₁₂H₁₀BrNO
• Molecular Weight: 264.1179
• Product Categories: Halides;Pyridines
• Mol File: 452972-07-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 346.4°C at 760 mmHg
• Flash Point: 163.3°C
• Appearance: /
• Density: 1.403g/cm³
• Vapor Pressure: 0.000116mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-BROMO-5-(4-METHOXYPHENYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-(4-METHOXYPHENYL)PYRIDINE(452972-07-5)
• EPA Substance Registry System: 3-BROMO-5-(4-METHOXYPHENYL)PYRIDINE(452972-07-5)

Safety Data

• Hazardous Substances Data: 452972-07-5(Hazardous Substances Data)

Usage

General Description

3-Bromo-5-(4-methoxyphenyl)pyridine is a chemical compound used in organic synthesis and pharmaceutical research. It belongs to the class of pyridine derivatives and is characterized by the presence of a bromine and a methoxyphenyl group on the pyridine ring. 3-BROMO-5-(4-METHOXYPHENYL)PYRIDINE has potential applications in the development of new drugs and agrochemicals due to its pharmacological and biological activities. Additionally, it can be utilized as a building block for the synthesis of more complex molecules. However, it is important to handle this chemical with care, as it is a potential irritant and may pose health risks if not handled properly.

InChI:InChI=1/C12H10BrNO/c1-15-12-4-2-9(3-5-12)10-6-11(13)8-14-7-10/h2-8H,1H3

Upstream product

• 452972-09-7 (5-bromopyridin-3-yl)boronic acid 
• 452972-13-3 2-[(5-bromo)pyridin-3-yl]-4,4',5,5'-tetramethyl-1,3-dioxaborolane 
• 625-92-3 3,5-dibromopyridine 
• 5720-07-0 4-methoxyphenylboronic acid 
• 33397-21-6 tris(4-methoxyphenyl)bismuth 
• 626-55-1 3-Bromopyridine 
• 696-62-8 para-iodoanisole 

Downstream Products

• 1037551-95-3 4-(5-bromopyridin-3-yl)phenol 
• 1171891-09-0 3-(4-methoxy-phenyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine 
• 1194450-31-1 8-[5-(4-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 

Relevant articles and documents

Regioselective Amination or Alkoxylation of Halogenated Amino-, Thio- or Alkoxypyridines via Pyridyne Intermediates

The treatment of 3-halopyridines (Cl, Br) bearing an R-substituent in position 2 (R = OEt, NEt2, N-piperidyl, or SEt) or in position 5 (R = OMe, OEt, SEt, NMe2, NEt2, or aryl) with KHMDS and an amine at 25 C for 12 hours in THF provided regioselectively 3

Fine-tuning the selectivity of aldosterone synthase inhibitors: Structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1- ij ]quinolin-4-one derivatives

Pyridine substituted 3,4-dihydro-1H-quinolin-2-ones (e.g., 1-3) constitute a class of highly potent and selective inhibitors of aldosterone synthase (CYP11B2), a promising target for the treatment of hyperaldosteronism, congestive heart failure, and myocardial fibrosis. Among these, ethyl-substituted 3 possesses high selectivity against CYP1A2. Rigidification of 3 by incorporation of the ethyl group into a 5- or 6-membered ring affords compounds with a pyrroloquinolinone or pyridoquinolinone molecular scaffold (e.g., 4 and 5). It was found that these molecules are even more potent and selective CYP11B2 inhibitors than their corresponding open-chain analogues. Moreover, pyrroloquinolinone 4 exhibits no inhibition of the six most important hepatic CYP enzymes as well as a bioavailability in the range of the marketed drug fadrozole. The SAR studies disclose that subtle changes in the heterocyclic moiety are responsible for either a strong or a weak inhibition of the highly homologous 11-hydroxylase (CYP11B1). These results are not only important for fine-tuning the selectivity of CYP11B2 inhibitors but also for the development of selective CYP11B1 inhibitors that are of interest for the treatment of Cushing's syndrome and metabolic syndrome.

Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents

We here report the synthesis and biological evaluation of new 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine designed as potential CDK inhibitors. Indole, 5-hydroxyindole, and phenol derivatives were used to generate three substitutions o